Amgen Inc (AMGN)

172.50
NASDAQ : Health Care
Prev Close 173.82
Day Low/High 170.96 / 174.13
52 Wk Low/High 133.64 / 184.21
Avg Volume 3.33M
Exchange NASDAQ
Shares Outstanding 735.40M
Market Cap 127.83B
EPS 10.30
P/E Ratio 16.51
Div & Yield 4.60 (2.60%)

Latest News

Biotech Movers: Regeneron Slides Back After Big Gains

Biotech Movers: Regeneron Slides Back After Big Gains

The main headwind for Regeneron is that Swiss pharma giant Novartis could soon be a rival to the eye drug that drives most of Regeneron's revenue.

Dems Roast Trump for Leaving Medicare Out of Drug Price Order

Dems Roast Trump for Leaving Medicare Out of Drug Price Order

The main thrust of the order appears to be easing regulatory hurdles to drug approvals, which could lower the cost of bringing new treatments to market and thus lower prices.

Amgen Defends Drug Pipeline, Says the Best is Yet to Come

Amgen Defends Drug Pipeline, Says the Best is Yet to Come

Slowing sales and safety concerns have some investors less than enthused, but Amgen says it's drugs in development could deliver.

Amgen To Present New Data At 22nd Congress Of The European Hematology Association

Oral Presentation of Phase 3 Data Shows KYPROLIS® (Carfilzomib) and Dexamethasone Improved Median Overall Survival by 7.6 Months Compared to Velcade® (Bortezomib) and Dexamethasone in Relapsed Multiple Myeloma

Intermediate Trade: QQQ

Intermediate Trade: QQQ

Consider this bearishly biased, August put spread.

Pharmaceutical Stocks Gain on Promising Migraine Drugs with Hefty Price Tags

Pharmaceutical Stocks Gain on Promising Migraine Drugs with Hefty Price Tags

Newly released neurotransmitter research could open up a $8 - $10 billion market as early as next year.

The Hustle and Bustle of Russell

So far this month it has outperformed Nasdaq.

Amgen Presents Erenumab Data At The 59th Annual Scientific Meeting Of The American Headache Society

Data From Broad Clinical Program Show Investigational Erenumab is Effective at Preventing Migraine in Patients Experiencing Four or More Migraine Days a Month

With Solid Base, Amgen Keeps Climbing

With Solid Base, Amgen Keeps Climbing

The stock is set up well for more upside and remains very near a low-risk buy zone.

Amgen Wants to Boost Label on Powerhouse Repatha

Amgen Wants to Boost Label on Powerhouse Repatha

The day before Amgen appeared in court, the biopharma giant announced a submission to change its label on powerhouse drug Repatha.

Amgen Submits Regulatory Applications For Repatha® (evolocumab) Cardiovascular Outcomes Data In US And Europe

Applications Based on Data From Repatha Cardiovascular Outcomes Study Showing an Additional Reduction in Heart Attacks, Strokes and Coronary Revascularizations on Top of Optimized Statin Therapy

Amgen Presents New Data From Phase 3 XGEVA® (Denosumab) Study In Patients With Multiple Myeloma At ASCO 2017

Analysis Demonstrated XGEVA had a Significantly Lower Rate of Renal Adverse Events Compared to Zoledronic Acid

Amgen Presents New Phase 2 Data On IMLYGIC® (Talimogene Laherparepvec) Investigational Combination At ASCO 2017

First Randomized Study to Evaluate the Combination of IMLYGIC, an Oncolytic Viral Therapy, With a Checkpoint Inhibitor

Amgen Showcases A Legacy Of Science, Innovation And Collaboration In Cambridge

Massachusetts Governor Charles Baker and U.S. Senator Edward Markey Join Members of the Life Sciences Community at Newly Expanded Facility in Kendall Square

Intermediate Trade: QQQ

Intermediate Trade: QQQ

The tactic is the bearishly biased, calendar diagonal call spread, which controls the risk of the trade.

Amgen Osteoporosis Drug Approval Plan Derailed Over Heart Safety Risk -- Jim Cramer Weighs In

Amgen Osteoporosis Drug Approval Plan Derailed Over Heart Safety Risk -- Jim Cramer Weighs In

Amgen's osteoporosis setback will likely be seen as providing a commercial boost to Radius Health, which secured U.S. approval in April for a competing osteoporosis drug, Tymlos.

Biotech Movers: Radius Health, Amgen, Paratek

Biotech Movers: Radius Health, Amgen, Paratek

Radius Health, Amgen and Paratek Pharmaceuticals were among the biotech movers in premarket trading on Monday.

Wake Up Wall Street: Political Upheaval Surrounding President Trump Shows No Sign of Abating

Wake Up Wall Street: Political Upheaval Surrounding President Trump Shows No Sign of Abating

Wake Up Wall Street: Political Upheaval Surrounding President Trump Shows No Sign of Abating

UCB Stock Plunges After Trials Reveal Safety Risk in Amgen JV

UCB Stock Plunges After Trials Reveal Safety Risk in Amgen JV

UCB stock plummeted Monday after clinical trials shone a light over a possible safety risk related to the Osteoporosis treatment that it has been developing alongside Amgen

Amgen And UCB Announce Top-Line Phase 3 Data From Active-Comparator Study Of EVENITY™ (Romosozumab) In Postmenopausal Women With Osteoporosis

ARCH Study Met Primary and Key Secondary Endpoints by Reducing the Incidence of New Vertebral, Clinical and Non-Vertebral Fractures

Repatha® (Evolocumab) Reduced Cardiovascular Events In Patients With Baseline LDL-C Levels Below Current Targets

New Analysis From Cardiovascular Outcomes Trial Shows Addition of Repatha in Patients Considered at Goal Further Reduces Cardiovascular Event Risk